Shanghai Zheye Biotechnology LLC has discovered new phenylpropionic acid derivatives acting as apolipoprotein A (ApoA; LPA)/apolipoprotein B-100 (APOB) interaction inhibitors potentially useful for the treatment of stroke, atherosclerosis, thrombosis, coronary heart disease and aortic valve stenosis.
Adlai Nortye Biopharma Co. Ltd. and Adlai Nortye Pte Ltd. have synthesized new GTPase KRAS G12C mutant inhibitors potentially useful for the treatment of cancer, autoimmune disorders and inflammatory disorders.
Monte Rosa Therapeutics AG has reported new molecular glue degraders comprising an E3 ubiquitin-protein ligase-binding moiety acting as E3 G1/S-specific cyclin-E1 (CCNE1)/cereblon interaction inducers and CCNE1 degradation inducers potentially useful for the treatment of cancer.
Bayer AG has patented new potassium channel Kir3.4 (GIRK4; KCNJ5) and/or Kir3.1/3.4 (GIRK1/4; KCNJ3/5) blockers potentially useful for the treatment of heart failure, arrhythmia, primary hyperaldosteronism and hypertension.
Hexapharmatec Co. Ltd. has discovered new transcription factor EB (TFEB) inducers described as potentially useful for the treatment of colitis, kidney and hepatic fibrosis.
Yaoya Technology (Shanghai) Co. Ltd. has discovered new pyrimidothiopyrandione GTPase KRAS G12D mutant inhibitors potentially useful for the treatment of cancer.
Blueprint Medicines Corp. has identified new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a cyclin-dependent kinase 4 (CDK4)-targeting moiety potentially useful for the treatment of cancer.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has synthesized new Kelch-like ECH-associated protein 1 (KEAP1) activators and nuclear factor erythroid 2-related factor 2 (NRF2) degradation inducers potentially useful for the treatment of cancer.
RSS